Navigation Links
Alexza Receives Complete Response Letter for Adasuve™ NDA
Date:5/3/2012

ccess the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PG7Q7BCVY.

To access the live conference call via phone, dial 888-679-8040.  International callers may access the live call by dialing +1-617-213-4851.  The reference number to enter the call is 19038430. 

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or +1-617-801-6888 for international callers.  The reference number for the replay of the call is 44033163.  A replay of the call will be available for two weeks following the event.

About Alexza Pharmaceuticals, Inc.
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE™ (Staccato loxapine) is Alexza's lead pro
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... I Results Offer Hope of First Highly Effective Drug in ... June 1 Roche announced today results from a Phase ... promising treatment for patients with advanced melanoma whose cancer harbours ... PLX4032 lived for a median of at least six months ...
... Eli Lilly and Company announced today that Phase ... (gemcitabine HCl for injection) to the current standard of ... at three years for women with locally advanced cervical ... commonly diagnosed women,s cancer, and the second most common ...
Cached Medicine Technology:Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 2Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 3Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 4Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6
(Date:7/12/2014)... 2014 For those who are unfamiliar with ... absorb the nutrients in food. The enzymes literally break up ... enough to be absorbed by human bodies. According Dr. Henry ... enzymes in regular food is the cause of many gastrointestinal ... started by Michelle DelPresto, a mother of 3 who is ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... York, NY (PRWEB) July 12, 2014 As ... (the National Institute of Standards and Technology), the June 25th, ... the electronic discovery world. It was also ... finally in, depending on whether it was seen from an ... But this much is fact, there is now precedent which ...
(Date:7/12/2014)... July 12, 2014 Dubai is buzzing ... legend is heading to the UAE. The National ... will be in the UAE from 28-31 October to ... support of diabetes awareness. The event is being organized ... and event management company based in Dubai. The announcement ...
(Date:7/12/2014)... 2014 Praeclarus Press is ... a valuable new resource for women in need of ... women work away from their children. Today’s mothers receive ... of breastfeeding, but often feel unsupported when it comes ... With its evidence-based insights, and written by Nancy Mohrbacher, ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... the same doctor during their first six months of ... screenings -- for lead poisoning, anemia and tuberculosis -- ... repeatedly by the same physician, often referred to as ... the children they studied. , Researchers from The Children,s ...
... Corporation of,North America, its U.S. subsidiary, MGI PHARMA, ... U.S. Food and Drug Administration,(FDA) has approved Aloxi(R) ... and vomiting (PONV) for up to 24 hours,following ... demonstrated., Aloxi, available in the United States ...
... the cause of a Hutchinson-Gilford Progeria Syndrome (HGPS), a ... to researchers at the National Cancer Institute (NCI), part ... findings, the first to indicate a biological basis for ... may also provide new insights into the biological mechanisms ...
... WATERBURY, Conn., March 2 Therap Services announces the,release ... and reporting applications. Therap version 7.2 will feature,new forms ... the Health,Tracking module and the Emergency Medical/Behavior Intervention Strategies,(EMBIS) ... in version 7.2 include: -- Behavior Plan and ...
... mirrors growth of disease, study says , , FRIDAY, Feb. ... between rising rates of carbohydrate intake and obesity and ... United States, a new study says. , Researchers noted ... 1973 to 2.1 million in 2001, which closely mirrors ...
... treatment and alcohol, drug use , , SATURDAY, March 1 ... for attention deficit-hyperactivity disorder (ADHD) might have one less thing ... kids are no more likely than their peers to abuse ... which was funded by the National Institutes of Health, is ...
Cached Medicine News:Health News:In early childhood, continuous care by 1 doctor improves delivery of health screenings 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 3Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 4Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 5Health News:Adult stem cell changes underlie rare genetic disease associated with accelerated aging 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 3Health News:ADHD Drugs Won't Raise Risk of Substance Abuse 2Health News:ADHD Drugs Won't Raise Risk of Substance Abuse 3
... The word cohesive is a new term being used ... to the more liquid fill that may have been ... is not new science, this is not new technology ... today to describe the sticking together nature of the ...
Nasal Implants are used to augment the shape or reshaping of the nose....
Inquire...
Inquire...
Medicine Products: